The announcement was welcomed by pharmaceutical and medical technology companies, COCIR, EFPIA, EuropaBio, MedTech Europe and Vaccines Europe.
The future partnership hopes to demonstrate to researchers, patients, and citizens, that Europe has the ambition to be a world-leader in collaborative research and development.
The Covid-19 pandemic has highlighted the importance of working together to tackle global public health threats. By investing in collaborative research and development, both Europe’s health systems’ resilience and sustainability will be improved. Additionally, the needs of patients will be better addressed.
The Partnership Proposal details objectives and deliverables, as well as governance and the operational model. The document aims to provide an insight into topics which will be looked into further in the draft partnership legislation which is expected in Autumn 2020.
The new partnership will also aim to create synergies and complement other features of the European research landscape, in particular with the EU-Africa Global Health Partnership, potential co-funded partnerships on ‘Health and Care Systems Transformation’, the European Partnership for One Health/AMR and ‘Pandemic Preparedness and Societal Resilience’, and with the EU4Health Programme.